QualityStocks would like to highlight Zynex, Inc. (OTCBB: ZYXI). The company operates under three primary business segments; Zynex Medical, Zynex NeuroDiagnostics and Zynex Monitoring Solutions. Zynex Medical engineers, manufactures, markets and sells its own design of electrotherapy medical devices for electrotherapy, used for pain management and rehabilitation. Zynex Medical’s product lines are fully developed, FDA-cleared and commercially sold world-wide. Zynex NeuroDiagnostics, sells the company's proprietary NeuroMove device designed to help stroke and spinal cord injury patients and is currently expanding into markets for EMG, EEG, sleep pattern, auditory and nerve conductivity neurological diagnosis devices through product development and acquisitions. Zynex Monitoring Solutions, currently in the development stage, has been established to develop and market medical devices for non-invasive cardiac monitoring.
In the company’s news yesterday,
Zynex announced its acquisition of substantially all the assets of NeuroDyne Medical Corp., through its subsidiary Zynex NeuroDiagnostics Inc., effective March 9, 2012.
NeuroDyne is a Massachusetts-based manufacturer of advanced medical devices, which can be used for evaluation and treatment of neurological and neuromuscular disorders, as well as for education and research purposes. The company’s product line includes medical instruments, sensors, disposable electrodes, and software that offer sEMG, EKG, EEG, respiration, skin temp, EDR, EDL, peripheral blood flow, IBI, heart rate, and heart rate variability.
NeuroDyne’s products are sold and used by healthcare providers, educators, and researchers, and as such, the company’s customers include some of the top health services providers in the country.
Thomas Sandgaard, CEO of Zynex, acknowledged the benefits of the acquisition in regards to product expansion and sales networking.
“This acquisition is important for us as it adds established product lines and sales channels that we expect will fuel growth in our NeuroDiagnostics division. Our long-term goal is to generate sales and profits in our NeuroDiagnostics division that will match our electrotherapy division, Zynex Medical. Products in Zynex NeuroDiagnostics are sold domestically to clinics and hospitals as capital goods, and internationally through distributors,” Sandgaard stated in the press release.
Per the agreement, Zynex acquired NeuroDyne’s for $320,000 payable at closing ($145,000 in cash and $175,000 in restricted common stock), in addition to $100,000 in cash payable 60 days from the closing date. The deal also includes a seven year earn-out incentive, based on a percentage of net revenue generated by NeuroDyne products.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.